Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Prognosis of Recurrence after Complete Resection in Early-Stage Non-Small Cell Lung Cancer

  • Choi, Pil Jo (Department of Thoracic and Cardiovascular Surgery, Dong-A University College of Medicine) ;
  • Jeong, Sang Seok (Department of Thoracic and Cardiovascular Surgery, Dong-A University College of Medicine) ;
  • Yoon, Sung Sil (Department of Thoracic and Cardiovascular Surgery, Dong-A University College of Medicine)
  • Received : 2013.04.29
  • Accepted : 2013.09.17
  • Published : 2013.12.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Tumor recurrence is the most common cause of treatment failure, even after complete resection of early-stage non-small cell lung cancer (NSCLC). In this study, we investigated the prognosis of patients with early recurrence in order to identify independent risk factors related to early recurrence. Methods: Between February 1995 and December 2012, 242 patients who underwent surgical resection for stage I NSCLC at Dong-A University Hospital were reviewed. The factors predicting overall survival (OS) and early recurrence were investigated. We also investigated the relationship between the patterns and period of recurrence and clinicopathological factors. Results: For patients with stage IA and IB NSCLC, the 5-year OS rate was 75.7% and 57.3% (p=0.006), respectively. A multivariate Cox proportional hazards model demonstrated that gender (p=0.004), comorbidity number (p=0.038), resection type (p=0.002), and tumor size (p=0.022) were the statistically significant predictors of OS. Moreover, the multivariate analysis revealed that smoking history (p=0.023) and histologic grade (p=0.012) were the independent predictors of early recurrence. Additionally, only histologic grade (poor differentiation) was found to be significantly associated with a higher frequency of distant metastasis; there was no relationship between the patterns and period of recurrence and clinicopathological factors. Conclusion: The present study demonstrated that smoking history and histologic grade were independent prognostic factors for early recurrence within two years in patients with early-stage NSCLC. Patients with these predictive factors may be good candidates for adjuvant therapy.

Keywords

References

  1. Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. Cancer 2000; 89(11 Suppl):2334-44. https://doi.org/10.1002/1097-0142(20001201)89:11+<2334::AID-CNCR4>3.0.CO;2-I
  2. Goodgame B, Stinchcombe TE, Simon G, Wozniak A, Govindan R. Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). J Thorac Oncol 2009;4: 1293-300. https://doi.org/10.1097/JTO.0b013e3181b7ef95
  3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57. https://doi.org/10.1378/chest.122.3.1037
  4. Pollack JR. A perspective on DNA microarrays in pathology research and practice. Am J Pathol 2007;171:375-85. https://doi.org/10.2353/ajpath.2007.070342
  5. Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg 2006;81:1958-62. https://doi.org/10.1016/j.athoracsur.2005.12.054
  6. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9. https://doi.org/10.1016/S0022-5223(95)70427-2
  7. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96. https://doi.org/10.1002/1097-0142(19950901)76:5<787::AID-CNCR2820760512>3.0.CO;2-Q
  8. Nakagawa T, Okumura N, Ohata K, Igai H, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 34:499-504. https://doi.org/10.1016/j.ejcts.2008.05.016
  9. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-17. https://doi.org/10.1016/j.athoracsur.2006.08.046
  10. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-6. https://doi.org/10.1136/thx.2007.094912
  11. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest 2011;139:855-61. https://doi.org/10.1378/chest.10-1535
  12. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 1980;80: 390-9.
  13. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331-8. https://doi.org/10.1016/S0003-4975(10)62281-3
  14. Thomas P, Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1990;49:242-6. https://doi.org/10.1016/0003-4975(90)90145-V
  15. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. https://doi.org/10.1200/JCO.2007.13.9030

Cited by

  1. Novel treatment options in stage I non-small-cell lung cancer vol.14, pp.9, 2014, https://doi.org/10.1586/14737140.2014.929500
  2. Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic vol.9, pp.7, 2013, https://doi.org/10.1371/journal.pone.0100244
  3. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging S vol.16, pp.6, 2015, https://doi.org/10.1016/j.cllc.2015.04.005
  4. Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer vol.7, pp.None, 2013, https://doi.org/10.2147/lctt.s85112
  5. Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer vol.17, pp.5, 2016, https://doi.org/10.1016/j.cllc.2015.12.013
  6. Design, Synthesis, and Evaluation of a Neurokinin-1 Receptor-Targeted Near-IR Dye for Fluorescence-Guided Surgery of Neuroendocrine Cancers vol.27, pp.9, 2013, https://doi.org/10.1021/acs.bioconjchem.6b00374
  7. Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer vol.6, pp.5, 2017, https://doi.org/10.1002/cam4.980
  8. Genetic Variants in One-Carbon Metabolism Pathway Predict Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer vol.98, pp.12, 2020, https://doi.org/10.1159/000509658
  9. Complex Network Characterization Using Graph Theory and Fractal Geometry: The Case Study of Lung Cancer DNA Sequences vol.10, pp.9, 2013, https://doi.org/10.3390/app10093037